{
  "docId": "019de517-9621-753c-9309-53e4583e2cc6",
  "docSlug": "143cc48f9205c993e313c869079cac0f",
  "documentTitle": "Avantor | Investor Day Presentation Deck | 91 slides",
  "authorId": "avantor",
  "authorName": "Avantor",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 55,
  "pageCount": 91,
  "prevPage": 54,
  "nextPage": 56,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-9621-753c-9309-53e4583e2cc6/55",
  "deckHref": "/decks/019de517-9621-753c-9309-53e4583e2cc6",
  "deckJsonHref": "/decks/019de517-9621-753c-9309-53e4583e2cc6.json",
  "deckAnchorHref": "/decks/019de517-9621-753c-9309-53e4583e2cc6#slide-55",
  "components": [
    {
      "bbox": {
        "h": 0.21,
        "w": 0.503,
        "x": 0.466,
        "y": 0.21
      },
      "kind": "chart",
      "text": "2023E TOTAL MARKET REVENUE FOR BIOLOGICS\n53% Monoclonal Antibodies\n8% GLP-1\n19% Other Protein Therapies\n3% Cell & Gene Therapies\n17% Other (e.g., mRNA)",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a872898e-4178-41bd-8761-3ed26a92e34f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.21,
        "x": 0.046,
        "y": 0.66
      },
      "kind": "list",
      "text": "New modalities: >2,000 active clinical projects",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03579d9d-b425-4a08-b963-b9b0b744d9f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.21,
        "x": 0.046,
        "y": 0.425
      },
      "kind": "list",
      "text": "mAbs: >30 new therapies approved in last 2 years, ~2,500 active clinical projects",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b0b79b0-2b28-4a83-8e46-b4e05a207f24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.102,
        "x": 0.288,
        "y": 0.28
      },
      "kind": "metric",
      "text": ">10%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d23c8c82-ccbf-4d90-a14b-be168bf2aa4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.043,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Source: Evaluate Pharma data as of November 2023. CAGRs represent estimated revenue growth from 2018 to 2028. mAbs include traditional mAbs and recombinant antibodies. GLP-1 therapies include dual agonist therapies. Other protein therapies include insulin. Other includes nucleic acids, vaccines, etc. 1. CAGR inflated due to COVID-19 vaccine forecast uncertainty.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df20d507-03c5-445b-9047-4221cd9a002c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.67,
        "x": 0.288,
        "y": 0.61
      },
      "kind": "table",
      "text": "CAGR:\nMonoclonal Antibodies >10%\nGLP-1 >20%\nOther Protein Therapies >2%\nCell & Gene Therapies >30%\nOther (e.g., mRNA) >12%¹",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fe507ff-00fa-4a80-af96-de0e5be2fe5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.62,
        "x": 0.043,
        "y": 0.06
      },
      "kind": "title",
      "text": "Robust fundamentals drive double-digit long-term end market growth",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e64974b-a81f-459f-8cbb-591b13324ecd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "067b7cf8-89fa-4ecd-bc00-bcfef91d89c0",
      "evidence": "The components list various biologics segments and their corresponding CAGR, which can be visualized in a 2x2 matrix.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 88,
      "from": 28,
      "beatId": "c818eb9e-f140-457e-953d-fc4ee5d48533",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck presents a comprehensive overview of Avantor's business segments, growth strategy, and financial performance, providing a sense of satisfaction and confidence in the company's future",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}